LGND Q2 2019 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M-72.2% YoY

Gross Profit

$23M90.4% margin

Operating Income

-$4M-16.5% margin

Net Income

-$14M-57.7% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

-42.5%

Cash Flow

Operating Cash Flow

-$61M

Free Cash Flow

-$61M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$760M

Stockholders' Equity

$1.0B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$90M	-72.2%
Gross Profit	$23M	$89M	-74.6%
Operating Income	-$4M	$70M	-105.9%
Net Income	-$14M	$73M	-119.7%